GSK to acquire liver disease drug candidate efimosfermin in deal worth up to $2bn
Efimosfermin is currently undergoing Phase III clinical trials for the treatment of metabolic dysfunction-associated steatohepatitis and alcohol-related liver disease

A leading resource for the Pharmaceutical industry since 2002
Efimosfermin is currently undergoing Phase III clinical trials for the treatment of metabolic dysfunction-associated steatohepatitis and alcohol-related liver disease
Give your business an edge with our leading industry insights.
Societal polarisation presents significant challenges for the pharmaceutical industry, affecting regulatory landscapes, public trust, innovation, and market dynamics
Effects of interstate armed conflicts on the pharmaceutical industry
Unveiling the impact of misinformation and disinformation in the pharmaceutical industry
The ripple effects of inflation on the pharmaceutical industry
Extreme weather events: The implications for the pharmaceutical industry